ETON Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 Mai 2024 @ 22:00):

Stats
Tagesvolumen	25 959.00
Durchschnittsvolumen	63 919.00
Marktkapitalisierung	93.00M
EPS	$0 ( 2024-05-13 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-90.50
ATR14	$0.0120 (0.33%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-13	Gruber James R.	Buy	144 677	Stock Option (Right to buy)
2024-02-13	Adams Jennifer Mckie	Buy	30 000	Stock Option (Right to buy)
2024-02-13	Brynjelsen Sean	Buy	438 633	Stock Option (Right to buy)
2024-02-13	Casamento Charles J	Buy	30 000	Stock Option (Right to buy)
2024-02-13	Krempa David	Buy	144 677	Stock Option (Right to buy)

INSIDER POWER
56.09
Last 96 transactions
Buy: 4 266 352 \| Sell: 3 981 653

Volumen Korrelation

Lang: 0.18 (neutral)

Kurz: -0.82 (strong negative)

Signal:(47.184) Neutral

Eton Pharmaceuticals Inc Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Eton Pharmaceuticals Inc Korrelation - Währung/Rohstoff

-0.40
( neutral )

0.40
( neutral )

0.00
( neutral )

-0.38
( neutral )

0.00
( neutral )

-0.52
( weak negative )

Eton Pharmaceuticals Inc Finanzdaten

Annual	2023
Umsatz:	$31.64M
Bruttogewinn:	$21.06M (66.56 %)
EPS:	$-0.0365

FY	2023
Umsatz:	$31.64M
Bruttogewinn:	$21.06M (66.56 %)
EPS:	$-0.0365

FY	2022
Umsatz:	$21.25M
Bruttogewinn:	$14.32M (67.38 %)
EPS:	$-0.390

FY	2021
Umsatz:	$21.83M
Bruttogewinn:	$19.21M (87.99 %)
EPS:	$-0.0800

Financial Reports:

No articles found.

Eton Pharmaceuticals Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Eton Pharmaceuticals Inc

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.